One might argue that our data are less relevant in the present era of promising data on the use of novel agents in CLL, notably Bruton’s tyrosine kinase inhibitors9,10, phosphatidylinositol-3-kinase inhibitors11 and BCL-2 antagonists12,13. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.